论文部分内容阅读
目的观察脉血康胶囊联合丹参川芎嗪注射液治疗短暂性脑缺血发作的临床疗效。方法选取2015年1月—2015年12月陕西省丹凤县医院收治的短暂性脑缺血发作患者106例,随机分为对照组和治疗组,每组各53例。对照组在常规治疗基础上静脉滴注丹参川芎嗪注射液,10 m L加入250 m L生理盐水,1次/d;治疗组在对照组的基础上口服脉血康胶囊,4粒/次,1次/d。两组患者均连续治疗4周。观察两组临床疗效,比较两组治疗前后凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、凝血酶时间(TT)、纤维蛋白原(FIB)、超敏C反应蛋白(hs-CRP)和D-二聚体指标水平。观察两组患者的不良反应和6个月内的复发情况。结果治疗后,对照组和治疗组的总有效率分别为69.81%、88.68%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组PT、APTT、TT水平均显著升高,FIB、hs-CRP、D-二聚体水平显著降低,同组治疗前后差异具有统计学意义(P<0.05);且治疗组这些观察指标的改善程度优于对照组,两组比较差异有统计学意义(P<0.05)。治疗组6个月复发率明显低于对照组,两组比较差异有统计学意义(P<0.05)。结论脉血康胶囊联合丹参川芎嗪注射液治疗短暂性脑缺血发作临床疗效确切,不良反应少,具有一定的临床推广应用价值。
Objective To observe the curative effect of Maishenkang capsule combined with injection of Salvia miltiorrhiza and ligustrazine on transient ischemic attack. Methods From January 2015 to December 2015, 106 patients with transient ischemic attack admitted to Danfeng County Hospital of Shaanxi Province were randomly divided into control group and treatment group, with 53 cases in each group. The control group was treated with intravenous infusion of Salviae Miltiorrhizae and Ligustrazine Injection on the basis of conventional treatment and 250 m L normal saline at 10 mL for 1 d. 1 time / d. Two groups of patients were treated for 4 weeks. The clinical efficacy of the two groups was observed. The changes of prothrombin time (PT), APTT, TT, fibrinogen (FIB), hs -CRP) and D-dimer levels. Adverse reactions and relapse within 6 months in both groups were observed. Results After treatment, the total effective rates of the control group and the treatment group were 69.81% and 88.68%, respectively. There was significant difference between the two groups (P <0.05). After treatment, the levels of PT, APTT and TT in both groups were significantly increased, and the levels of FIB, hs-CRP and D-dimer were significantly decreased in the two groups (P <0.05); and those in the treatment group The improvement of observation index was better than that of the control group, the difference between the two groups was statistically significant (P <0.05). The recurrence rate of the 6-month treatment group was significantly lower than that of the control group, the difference between the two groups was statistically significant (P <0.05). Conclusion Maishenkang capsule combined with injection of Salvia miltiorrhiza and ligustrazine for the treatment of transient ischemic attack has definite clinical curative effect and few adverse reactions and has some clinical application value.